All In Biotech

BLA 103628 · Biogen

Avonex

Interferon Beta-1a · Interferon beta

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 17, 1996

Approved uses

6

Original approval plus efficacy supplements

Registered trials

165

55 Phase 3, 3 recruiting

FAERS reports

146,156

66,610 serious, 7,095 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 19, 2025.

AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AVONEX is for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 2020 Supplement 5263 · Efficacy LetterLabel
  • Feb 27, 2012 Supplement 5189 · Efficacy LabelLetter
  • Feb 27, 2012 Supplement 5191 · Efficacy LabelLetter
  • Jan 31, 2003 Supplement 5001 · Efficacy OrphanLabelLetter
  • Nov 12, 2002 Supplement 5008 · Efficacy OrphanLabelLetter
  • May 17, 1996 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetterLabel
1 products under this application
  • AVONEX · INTERFERON BETA-1A 30UG/ML · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Interferon Beta-1a" as an intervention, any sponsor and status, largest first.

All 165 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • multiple sclerosis relapse11,981
  • influenza like illness10,427
  • fatigue8,660
  • fall8,142
  • multiple sclerosis7,730
  • gait disturbance7,252
  • memory impairment7,181
  • headache6,037
  • pain5,895
  • asthenia4,774
  • malaise4,079
  • drug ineffective4,051

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,740
20054,860
20063,370
20073,169
20084,352
20094,536
201013,680
201112,126
201214,126
201320,049
201414,664
20158,509
20168,747
20176,619
20185,772
20194,547
20203,934
20212,690
20222,369
20232,070
20241,427
20251,156
2026619

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Avonex* (Interferon Beta-1a*) · HCPCS Q3027

2024 spending

$527K

Beneficiaries

n/a

271 claims

Per beneficiary

n/a

2024 ASP limit $55.33 per unit

View as table
YearSpending
2020$1,234,576
2021$855,047
2022$617,586
2023$543,024
2024$526,608

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 486 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.